Ryzolt approved for moderate to moderately severe chronic pain

The FDA has approved once-daily Ryzolt (tramadol HCl extended release tablets, from Labopharm) for the management of moderate to moderately severe chronic pain in adults who require around-the-clock pain treatment for an extended period of time. Ryzolt uses Labopharm’s patented Contramid controlled-release technology, which is a dual-matrix delivery system with both immediate-release and extended-release characteristics.

Ryzolt is expected to be available in the second quarter of 2009 in 100mg, 200mg and 300mg dosage strengths.

For more information call (888) 686-1017 or visit www.labopharm.com.